Global Statistics Representing LDL Test Market Scenario
Low-density lipoprotein, considered as bad cholesterol, builds-up in arteries, effectively clogging them and ultimately, leading to a stroke or a heart attack. The LDL test determines the risk of heart related diseases and disorders.
Heart diseases such as high-pressure, angina, stroke, carotid artery disease, and peripheral arterial disease have become prevalent due to high cholesterol levels. According to the Centers for Disease Control and Prevention (CDC), approximately 1 of every 13 Americans aged above 18 years has been diagnosed with coronary artery disease (CAD). High cholesterol level leads to hypertension and is thus, a menace worldwide. Diabetes reduces the good cholesterols and raises bad cholesterols and triglycerides, that increases the risk for stroke and heart diseases. Thus, high prevalence of diabetes globally is also one of the market drivers. For instance, according to the World Health Organization (WHO), approximately 422 million people suffer from diabetes around the globe.
Apart from this, lifestyle changes such as smoking and alcohol consumption have been leading to an increase in the prevalence of chronic diseases such as diabetes and higher cholesterol levels, which is further expected to provide a fillip to the demand for LDL test in the coming years.
The global LDL test market accounted for over USD 6,500 million in 2017 and is expected to grow at a CAGR of 6.5% during the forecast period, 2019–2026.
The global LDL test market can be segmented by type, component, application, and end user.
Based on type, the market can be segmented into LDL-C, LDL-P, LDL-B, and others. The LDL-C segment is expected to hold a major market share during the forecast period, owing to the increasing incidences of high cholesterol levels among the population.
Based on component, the market can be segmented into devices, kits & reagents and others. The kits & reagents segment is expected to hold a major market share during the forecast period. The kits & reagents segment has been further sub-segmented into toxicity assays kit, blood chemistry assays kit, and cytotoxicity assays kit. The devices segment has been further sub-segmented into syringes & needles, spectrophotometers and others.
On the basis of application, the market can be segmented into atherosclerosis, obesity, dyslipidemia, diabetes, angina, stroke, carotid artery disease, peripheral arterial disease, and others. The obesity segment is expected to hold a major market share, owing to the increasing number of people suffering from obesity around the globe.
Based on end user, the market can be segmented into hospitals, clinics, pharmaceutical and biotechnological companies, and diagnostic centers. The diagnostic centers segment is expected to hold a major market share during the forecast period.
Geographically, the global LDL test market has been segmented into North America, Europe, Asia Pacific, and Latin America, and the Middle East & Africa (LAMEA).
North America is expected to hold a major market share due to the increasing obesity among the population in the region. Increasing prevalence of obesity, especially in children, due to various factors such as unhealthy lifestyle and changing eating habits has also been playing a major role. According to the CDC, in 2014, more than one-third (36.5%) of the U.S. population was obese. Growing awareness about obesity and its effects on the human body is expected to support market growth in the coming years.
Europe is expected to be the second largest shareholder in the global LDL test market, owing to increasing incidences of heart diseases and issues such as ischemic heart disease, angina, unstable angina, myocardial infarction, and sudden cardiac death in the region. According to the British Heart Foundation, during 2014–2016, over 66,000 fatalities were reported due to coronary heart disease in the U.K. Apart from this, increasing prevalence of diabetes and obesity are further contributing to the growth of the LDL market.
Asia Pacific (APAC) is expected to be the fastest growing region during the forecast period, 2019–2026. In developing countries, increasing prevalence of obesity and high cholesterol levels have been contributing to the increasing incidences of heart diseases. In India, rising incidences of hypertension have been leading to the prevalence of cardiac diseases, which is expected to support market growth. According to the International Diabetes Federation, in 2017, approximately 8.8% of India’s population suffered from diabetes.
The LAMEA region is expected to witness sluggish growth, owing to undeveloped healthcare infrastructure. Additionally, a lack of awareness regarding the benefits of a healthy lifestyle is also hampering market growth. In the Middle East and Africa region, increasing per capita income, development of healthcare infrastructure are expected to drive market growth in the coming years.
Some of the major players in the LDL test market include Hoffmann-La Roche Ltd, Sekisui Diagnostics, Express Biotech International, Sigma-Aldrich Co. LLC, Randox Laboratories Ltd, Reckon Diagnostics, Quest Diagnostics Incorporated, DiaSys Diagnostics India Private Limited, Eurofins Scientific, Kopibeskyttet Unilabs Labhåndbok, Atlas Medical,Eurolyser Diagnostica GmbH, Laboratory Corporation of America, Diazyme Laboratories, Inc., and Thermo Fisher Scientific Inc.
LDL Test Market Segmentation
By End User
Why buy this report right now?